Lijun Xue

Lijun Xue

Auto-generated profile, based on publicly available information

Lijun Xue

City of Hope Comprehensive Cancer Center, Duarte, CA, USA

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2007 in Cancer Research
Verified
Journal Article
Open access
PDF file
LXLijun Xue
Lijun Xue
BZBingsen Zhou
Bingsen Zhou
XLXiyong Liu
Xiyong Liu
YHYvonne Heung
Yvonne Heung
JCJennifer Chau
Jennifer Chau
YYYun Yen
Yun Yen
P53R2, which is one of the two known ribonucleotide reductase small subunits (the other being M2), is suggested to play an important role in supplying deoxynucleotide triphosphates (dNTP) for DNA repair during the G1 or G2 phase of the cell cycle. The ability of p53R2 to supply dNTPs for repairing DNA damages requires the presence of a functional p53 tumor suppressor. Here, we report in vivo physical interaction and colocalization of p53R2 and p21 before DNA damage. Mammalian two-hybrid assay further indicates that the amino acids 1 to 113 of p53R2 are critical for interacting with the NH2-terminal region (amino acids 1–93) of p21. The binding between p21 and p53R2 decreases inside the nucleus in response to UV, the time point of which corresponds to the increased binding of p21 with cyclin-dependent kinase-2 (Cdk2), and the decreased Cdk2 activity in the nucleus at G1. Interestingly, p53R2 dissociates from p21 but facilitates the accumulation of p21 in the nucleus in response to UV. On the other hand, the ribonucleotide reductase activity increases at the corresponding time in response to UV. These data suggest a new function of p53R2 of cooperating with p21 during DNA repair at G1 arrest. [Cancer Res 2007;67(1):16–21]

11 September 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HZHang Zhang
Hang Zhang
XLXiyong Liu
Xiyong Liu
CWCharles David Warden
Charles David Warden
YHYasheng Huang
Yasheng Huang
SLSofia Loera
Sofia Loera
YYYun Yen
Yun Yen
Ribonucleotide reductase (RR) is an essential enzyme involved in DNA synthesis. We hypothesized that RR subunit M2 (RRM2) might be a novel prognostic and predictive biomarker for estrogen receptor (ER)-negative breast cancers. Individual and pooled survival analyses were conducted on six independent large-scale breast cancer microarray data sets; and findings were validated on a human breast tissue set (ZJU set). Gene set enrichment analysis revealed that RRM2-high breast cancers were significantly enriched for expression of gene sets that increased in proliferation, invasiveness, undifferentiation, embryonic stem/progenitor-like phenotypes, and poor patient survival (p < 0.01). Independent and pooled analyses verified that increased RRM2 mRNA levels were associated with poor patient outcome in a dose-dependent manner. The prognostic power of RRM2 mRNA was comparable to multiple gene signatures, and it was superior to TNM stage. In ER-negative breast cancers, RRM2 showed more prognostic power than that in ER-positive breast cancers. Further analysis indicated that RRM2 was a more accurate prognostic biomarker for ER-negative breast cancers than the pathoclinical indicators and uPA. A new RR inhibitor, COH29, could significantly enhance the chemosensitivity to doxorubicin in ER-negative MDA-MB-231 cells, but not in ER-positive MCF-7 cells. RRM2 appears to be a promising prognostic biomarker and therapeutic target for ER-negative breast cancer patients.

1 March 2003
Verified
Journal Article
Closed access
LXLijun Xue
Lijun Xue
BZBingsen Zhou
Bingsen Zhou
XLXiyong Liu
Xiyong Liu
WQWeihua Qiu
Weihua Qiu
ZJZhongchu Jin
Zhongchu Jin
YYYun Yen
Yun Yen

15 October 2003
Verified
Journal Article
Closed access
BZBingsen Zhou
Bingsen Zhou
XLXiyong Liu
Xiyong Liu
XMXueli Mo
Xueli Mo
LXLijun Xue
Lijun Xue
DDDana Darwish
Dana Darwish
YYYun Yen
Yun Yen

29 January 2015 in International Journal of Surgical Pathology
Verified
Journal Article
Closed access
DXDan Xue
Dan Xue
XLXiuzhen Li
Xiuzhen Li
YRYunqing Ren
Yunqing Ren
QLQi Liu
Qi Liu
YYYun Yen
Yun Yen
LXLijun Xue
Lijun Xue
Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a distinct entity from systemic ALCL (sALCL). sALCL usually shows immunohistochemical positivity for anaplastic lymphoma kinase (ALK) and epithelial membrane antigen (EMA), whereas these tests are negative in pcALCL. In contrast to sALCL, pcALCL is rarely found in children and young adults. We present here a case of a rare clinical condition in a 21-year-old woman, who has pcALCL with positive ALK and patchy EMA expression. She experiences a large, rapidly growing nodule without any outside-nodule manifestation. In conclusion, both ALK and EMA expression alone cannot distinguish pcALCL from secondary skin involvement by a sALCL.

30 January 2008
Verified
Journal Article
Closed access
CJChunling Jiang
Chunling Jiang
BZBingsen Zhou
Bingsen Zhou
KFKenneth Fan
Kenneth Fan
EHEric Heung
Eric Heung
LXLijun Xue
Lijun Xue
YYYun Yen
Yun Yen